Alberto Pilotto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alberto Pilotto has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- F Di Mario
Divisione di Gastroenterologia R Farini, Padova, Italy
8 shared publications - M. Rugge
Department of Oncological and Surgical Sciences, Cattedra di Istochimica e Immunoistochimica Patologica, ULSS 15 del Veneto, Italia
6 shared publications F Vianello
4 shared publications- Gioacchino Leandro
Gastroenterology Unit 1, Gastroenterological Hospital ‘S. De Bellis’ IRCCS, Castellana Grotte, Italy
4 shared publications M Franceschi
4 shared publicationsM. Franceschi
4 shared publications
Latest Publications
- 31 March 2008
- Published by Elsevier in Digestive and Liver Disease
- Vol. 40, S171-171
PO.1 NERD AND ERD: THE SCENARIO IS CHANGING OVER THE TIME? A 30 YEARS FOLLOW UP STUDY
- 31 March 2008
- Published by Elsevier in Digestive and Liver Disease
- Vol. 40, S171-171
PO.1 NERD AND ERD: THE SCENARIO IS CHANGING OVER THE TIME? A 30 YEARS FOLLOW UP STUDY
- 31 March 2008
- Published by Elsevier in Digestive and Liver Disease
- Vol. 40, S85-S86
PA.28 SERUM PEPSINOGEN I AS NON INVASIVE MARKER OF GASTRIC ACID SECRETION
- 31 March 2008
- Published by Elsevier in Digestive and Liver Disease
- Vol. 40, S85-S86
PA.28 SERUM PEPSINOGEN I AS NON INVASIVE MARKER OF GASTRIC ACID SECRETION
- 31 March 2008
- Published by Elsevier in Digestive and Liver Disease
- Vol. 40, S78
PA.7 CLINICAL VARIABILITY IN THE PRESENTATION OF THE GASTROESOPHAGEAL REFLUX DISEASE BEFORE THE HP ERA (STUDY FROM 1975 TO 1995)
- 31 March 2008
- Published by Elsevier in Digestive and Liver Disease
- Vol. 40, S78
PA.7 CLINICAL VARIABILITY IN THE PRESENTATION OF THE GASTROESOPHAGEAL REFLUX DISEASE BEFORE THE HP ERA (STUDY FROM 1975 TO 1995)
- Open Access
- 1 March 2000
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 29 (2) , 103-109
Review. Treatment of Helicobacter pylori infection in elderly subjects
A Pilotto, F Di Mario, M Franceschi; Treatment of Helicobacter pylori infection in elderly subjects., Age and Ageing, Volume 29, Issue 2, 1 March 2000, Pages 1
- 1 March 2000
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 29 (2) , 103-109
Open AccessReview. Treatment of Helicobacter pylori infection in elderly subjects
A Pilotto, F Di Mario, M Franceschi; Treatment of Helicobacter pylori infection in elderly subjects., Age and Ageing, Volume 29, Issue 2, 1 March 2000, Pages 1
- 1 July 1999
- Vol. 11 (7) , 801-8
Upper gastrointestinal diseases in the elderly: report of a meeting held at Vicenza, Italy, on 20 March 1998.
The aim of this article is to summarize the recent progress in geriatric/gastroenterological topics, particularly of the upper gastrointestinal tract, which were the focus of the First International Meeting on Upper Gastrointestinal Diseases in the Elderly, held in Vicenza, Italy, in March 1998. The Meeting was divided into three sections: gastro-oesophageal reflux disease (GORD) in the elderly, Helicobacter pylori infection in the elderly, and nonsteroidal anti-inflammatory drugs (NSAIDs) and the upper gastrointestinal tract in the elderly. GORD presents unique clinical features in elderly patients. The changes in oesophageal function, particularly disorders of motility, only partially explain its unique clinical manifestation. The diagnostic, clinical and therapeutic characteristics of GORD in the elderly need to be studied with attention to avoid its severe local complications, i.e. bleeding, stenosis and Barrett's oesophagus, as well as the more generalized risks of disability, impairment of nutritional status and reduction in the quality of life. Epidemiological studies have demonstrated that the prevalence of H. pylori infection increases with ageing and that subjects living in nursing homes have discrete epidemiological characteristics which render them a high-risk group. The incidence of some histological modifications of the gastric mucosa, particularly intestinal metaplasia, gastric atrophy and gastric cancer, seems to be both age- and H. pylori-related; their study in elderly subjects could give the key to understanding the pathophysiological mechanisms of H. pylori gastric damage. NSAID-related gastroduodenal damage, particularly haemorrhage, increases with age. Ageing, per se, does not modify significantly gastric aggressive factors, such as acid and pepsin secretions; however, a selective and specific reduction in some gastric defensive mechanisms seems to occur with ageing. Clinical studies on prevention of NSAID damage have rarely been performed in an elderly population, and meta-analyses of published data can lead to conflicting conclusions from a pharmaco-economic perspective. The identification of risk factors of NSAID-related gastroduodenal damage must be the foundation of preventive medical care for elderly subjects.
- 1 July 1999
- Vol. 11 (7) , 801-8
Upper gastrointestinal diseases in the elderly: report of a meeting held at Vicenza, Italy, on 20 March 1998.
The aim of this article is to summarize the recent progress in geriatric/gastroenterological topics, particularly of the upper gastrointestinal tract, which were the focus of the First International Meeting on Upper Gastrointestinal Diseases in the Elderly, held in Vicenza, Italy, in March 1998. The Meeting was divided into three sections: gastro-oesophageal reflux disease (GORD) in the elderly, Helicobacter pylori infection in the elderly, and nonsteroidal anti-inflammatory drugs (NSAIDs) and the upper gastrointestinal tract in the elderly. GORD presents unique clinical features in elderly patients. The changes in oesophageal function, particularly disorders of motility, only partially explain its unique clinical manifestation. The diagnostic, clinical and therapeutic characteristics of GORD in the elderly need to be studied with attention to avoid its severe local complications, i.e. bleeding, stenosis and Barrett's oesophagus, as well as the more generalized risks of disability, impairment of nutritional status and reduction in the quality of life. Epidemiological studies have demonstrated that the prevalence of H. pylori infection increases with ageing and that subjects living in nursing homes have discrete epidemiological characteristics which render them a high-risk group. The incidence of some histological modifications of the gastric mucosa, particularly intestinal metaplasia, gastric atrophy and gastric cancer, seems to be both age- and H. pylori-related; their study in elderly subjects could give the key to understanding the pathophysiological mechanisms of H. pylori gastric damage. NSAID-related gastroduodenal damage, particularly haemorrhage, increases with age. Ageing, per se, does not modify significantly gastric aggressive factors, such as acid and pepsin secretions; however, a selective and specific reduction in some gastric defensive mechanisms seems to occur with ageing. Clinical studies on prevention of NSAID damage have rarely been performed in an elderly population, and meta-analyses of published data can lead to conflicting conclusions from a pharmaco-economic perspective. The identification of risk factors of NSAID-related gastroduodenal damage must be the foundation of preventive medical care for elderly subjects.
- Open Access
- 1 July 1999
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 28 (4) , 367-371
Lack of association between Helicobacter pylori infection and extracardiac atherosclerosis in dyspeptic elderly subjects
BACKGROUND: There are conflicting data on the association between Helicobacter pylori (HP) infection and cardiovascular diseases. AIM: To determine if there is an association between gastric HP infection and atherosclerosis of cerebral or peripheral arteries in elderly subjects. METHODS: 90 dyspeptic elderly subjects had upper gastro-intestinal endoscopy and the gastroduodenal pathology was identified. HP infection was confirmed by gastric histology and the rapid urease test. Vascular ultrasonography of extracranial cerebral arteries and leg arteries was performed to evaluate (i) the presence of an atherosclerotic lesion, (ii) the total length of all plaques documented and (iii) the number of arteries with atherosclerotic lesions. Statistical analysis was by the chi2 test, Yates's corrected chi2 test, the Mann-Whitney test and logistic regression. RESULTS: 59 subjects were HP-positive. These had a higher prevalence of peptic ulcer disease (P = 0.01) and higher serum levels of IgG anti-HP antibodies (P = 0.0001), but no significant differences in the number of atherosclerotic lesions, the total length of the plaques or the number of arteries with lesions. No significant association of HP positivity was found with diabetes mellitus, hypertension, cigarette smoking or coronary heart disease, nor with serum concentrations of HDL-cholesterol, fibrinogen, triglycerides or glucose. CONCLUSIONS: Elderly dyspeptic subjects with gastric HP infection had significantly more peptic ulcer disease but no more atherosclerotic lesions than those who were HP-negative. Atherosclerosis was not associated with HP infection. In this cross-sectional study of elderly patients with dyspepsia, no association between HP infection and extracardiac atherosclerosis was found.
- 1 July 1999
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 28 (4) , 367-371
Open AccessLack of association between Helicobacter pylori infection and extracardiac atherosclerosis in dyspeptic elderly subjects
BACKGROUND: There are conflicting data on the association between Helicobacter pylori (HP) infection and cardiovascular diseases. AIM: To determine if there is an association between gastric HP infection and atherosclerosis of cerebral or peripheral arteries in elderly subjects. METHODS: 90 dyspeptic elderly subjects had upper gastro-intestinal endoscopy and the gastroduodenal pathology was identified. HP infection was confirmed by gastric histology and the rapid urease test. Vascular ultrasonography of extracranial cerebral arteries and leg arteries was performed to evaluate (i) the presence of an atherosclerotic lesion, (ii) the total length of all plaques documented and (iii) the number of arteries with atherosclerotic lesions. Statistical analysis was by the chi2 test, Yates's corrected chi2 test, the Mann-Whitney test and logistic regression. RESULTS: 59 subjects were HP-positive. These had a higher prevalence of peptic ulcer disease (P = 0.01) and higher serum levels of IgG anti-HP antibodies (P = 0.0001), but no significant differences in the number of atherosclerotic lesions, the total length of the plaques or the number of arteries with lesions. No significant association of HP positivity was found with diabetes mellitus, hypertension, cigarette smoking or coronary heart disease, nor with serum concentrations of HDL-cholesterol, fibrinogen, triglycerides or glucose. CONCLUSIONS: Elderly dyspeptic subjects with gastric HP infection had significantly more peptic ulcer disease but no more atherosclerotic lesions than those who were HP-negative. Atherosclerosis was not associated with HP infection. In this cross-sectional study of elderly patients with dyspepsia, no association between HP infection and extracardiac atherosclerosis was found.
- Open Access
- 1 July 1999
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 28 (4) , 412-414
Helicobacter pylori infection in elderly patients with peptic ulcer.
- 1 July 1999
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 28 (4) , 412-414
Open AccessHelicobacter pylori infection in elderly patients with peptic ulcer.
- 6 May 1999
- Vol. 46 (25) , 245-51
Rapid improvement of symptomatology with pantoprazole, amoxycillin and metronidazole in Helicobacter pylori-positive duodenal ulcer patients.
To evaluate the efficacy and tolerability of a new 1-week triple therapy regimen consisting of pantoprazole, amoxycillin and metronidazole. The study involved 51 Helicobacter pylori (H. pylori) positive patients (M:30, F:21, mean age: 52.5 years, range: 24-75) affected with duodenal ulcer in active phase. At baseline and 6 weeks after the completion of treatment, clinical assessment, endoscopy with gastric biopsies, rapid urease test, 13C urea breath test, and serum laboratory analyses were performed. All patients were treated with pantoprazole 40 mg once daily, plus amoxycillin 1 gram tid and metronidazole 250 mg tid for 1 week, and pantoprazole 40 mg once daily for a second week. A clinical diary for daily assessment of symptoms and side effects was completed by patients during the treatment period. Three patients were discontinued from the study. Six weeks after therapy, the ulcer was healed in 47 of 48 patients (97.9%, 95% CI = 93.9-100). The cure rates of H. pylori infection, expressed using both the intention-to-treat and per protocol analyses, were 80.4% (95% CI = 69.5-91.3) and 85.4% (95% CI = 75.4-95.4), respectively. The therapy led to a significant, rapid disappearance or reduction in daytime epigastric pain, from 68.8% on day 1 to 82.2% on day 3 (p < 0.001) and in nocturnal epigastric pain, from 80.6% on day 1 to 93.3% on day 3 (p < 0.001). After 2 weeks of treatment, the percentage of patients completely free of pain was 82.2% for daytime pain and 90.3% for nocturnal pain. A rapid improvement in acid regurgitation, heartburn, nausea and vomiting was also observed with a median value of symptom disappearance of 2 days. The percentages of patients completely symptom-free were 37.5% after 1 day, 54.1% after 3 days, 75% after 2 weeks, and 83.3% after 2 months. H. pylori-cured patients showed a significant decrease in the histological activity of both antral (p = 0.0001) and body (p < 0.008) gastritis. Mild to moderate adverse events were reported by 15 patients. One week triple therapy with pantoprazole in combination with amoxycillin and metronidazole, followed by a second week of pantoprazole, was well tolerated and highly effective for the 1) rapid improvement or resolution of symptoms; 2) healing of the DU; 3) eradication of H. pylori infection; and, 4) reduction of histological signs of chronic gastritis activity.
- 6 May 1999
- Vol. 46 (25) , 245-51
Rapid improvement of symptomatology with pantoprazole, amoxycillin and metronidazole in Helicobacter pylori-positive duodenal ulcer patients.
To evaluate the efficacy and tolerability of a new 1-week triple therapy regimen consisting of pantoprazole, amoxycillin and metronidazole. The study involved 51 Helicobacter pylori (H. pylori) positive patients (M:30, F:21, mean age: 52.5 years, range: 24-75) affected with duodenal ulcer in active phase. At baseline and 6 weeks after the completion of treatment, clinical assessment, endoscopy with gastric biopsies, rapid urease test, 13C urea breath test, and serum laboratory analyses were performed. All patients were treated with pantoprazole 40 mg once daily, plus amoxycillin 1 gram tid and metronidazole 250 mg tid for 1 week, and pantoprazole 40 mg once daily for a second week. A clinical diary for daily assessment of symptoms and side effects was completed by patients during the treatment period. Three patients were discontinued from the study. Six weeks after therapy, the ulcer was healed in 47 of 48 patients (97.9%, 95% CI = 93.9-100). The cure rates of H. pylori infection, expressed using both the intention-to-treat and per protocol analyses, were 80.4% (95% CI = 69.5-91.3) and 85.4% (95% CI = 75.4-95.4), respectively. The therapy led to a significant, rapid disappearance or reduction in daytime epigastric pain, from 68.8% on day 1 to 82.2% on day 3 (p < 0.001) and in nocturnal epigastric pain, from 80.6% on day 1 to 93.3% on day 3 (p < 0.001). After 2 weeks of treatment, the percentage of patients completely free of pain was 82.2% for daytime pain and 90.3% for nocturnal pain. A rapid improvement in acid regurgitation, heartburn, nausea and vomiting was also observed with a median value of symptom disappearance of 2 days. The percentages of patients completely symptom-free were 37.5% after 1 day, 54.1% after 3 days, 75% after 2 weeks, and 83.3% after 2 months. H. pylori-cured patients showed a significant decrease in the histological activity of both antral (p = 0.0001) and body (p < 0.008) gastritis. Mild to moderate adverse events were reported by 15 patients. One week triple therapy with pantoprazole in combination with amoxycillin and metronidazole, followed by a second week of pantoprazole, was well tolerated and highly effective for the 1) rapid improvement or resolution of symptoms; 2) healing of the DU; 3) eradication of H. pylori infection; and, 4) reduction of histological signs of chronic gastritis activity.
- 1 May 1999
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 14 (5) , 468-475
Efficacy of 7 day lansoprazole‐based triple therapy for Helicobacter pylori infection in elderly patients
Background: The prevalence of Helicobacter pylori increases with age. However, data regarding the effects of anti‐H. pylori treatments in the elderly are very scarce. Methods: To evaluate the effect of three lansoprazole‐based, 7 day, triple‐therapy regimens on H. pylori eradication rates, symptomatology, chronic gastritis activity and serological markers of H. pylori infection in elderly subjects, we studied 150 symptomatic patients over 60 years of age with H. pylori‐positive duodenal ulcer (DU, n = 34), gastric ulcer (GU, n = 19) or chronic gastritis (CG, n = 97). Patients were consecutively treated with one of the following regimens: (A) lansoprazole (LNS) 30 mg b.i.d. + clarithromycin (CLR) 250 mg b.i.d. + metronidazole (MTR) 250 mg q.i.d.; (B) LNS 30 mg b.i.d. + amoxycillin (AMOX) 1 g b.i.d. + MTR 250 mg q.i.d.; and (C) LNS 30 mg b.i.d. + CLR 250 mg b.i.d. + AMOX 1 g b.i.d. Results: Two months after therapy, the eradication rates of the three treatments, expressed using both intention‐to‐treat and per‐protocol analyses were, respectively; group A, 86 and 91.5%; group B, 80 and 87%; group C, 82 and 89.1%. After therapy, a significant reduction in epigastric pain (P < 0.001), heartburn (P = 0.02), dyspepsia (P < 0.001) and vomiting (P < 0.005) was observed independently of the success of H. pylori eradication. A significantly higher percentage of asymptomatic patients were in the GU‐DU group than in CG group (87.7 vs 70.0%, P = 0.032). After therapy, 33 subjects still suffered from symptoms. Persistence of symptoms was significantly associated with an endoscopic diagnosis of oesophagitis and not with H. pylori infection. Patients cured of H. pylori infection showed a significant decrease in the histological activity of both antral and body gastritis (P < 0.0001), a significant drop in immunoglobulin (Ig) G anti‐H. pylori antibodies (P < 0.0001) and pepsinogen (PG) C (P< 0.0001) and an increase in the PGA/PGC ratio (P < 0.0001). Conclusions: The 7 day, lansoprazole‐based triple therapy was well tolerated and highly effective in the cure of H. pylori infection, the reduction of symptoms, chronic gastritis activity and serum levels of IgG anti‐H. pylori antibodies and PGC. Persistence of symptoms after therapy was significantly higher in CG than GU and DU patients and was significantly associated with oesophagitis.
- 1 May 1999
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 14 (5) , 468-475
Efficacy of 7 day lansoprazole‐based triple therapy for Helicobacter pylori infection in elderly patients
Background: The prevalence of Helicobacter pylori increases with age. However, data regarding the effects of anti‐H. pylori treatments in the elderly are very scarce. Methods: To evaluate the effect of three lansoprazole‐based, 7 day, triple‐therapy regimens on H. pylori eradication rates, symptomatology, chronic gastritis activity and serological markers of H. pylori infection in elderly subjects, we studied 150 symptomatic patients over 60 years of age with H. pylori‐positive duodenal ulcer (DU, n = 34), gastric ulcer (GU, n = 19) or chronic gastritis (CG, n = 97). Patients were consecutively treated with one of the following regimens: (A) lansoprazole (LNS) 30 mg b.i.d. + clarithromycin (CLR) 250 mg b.i.d. + metronidazole (MTR) 250 mg q.i.d.; (B) LNS 30 mg b.i.d. + amoxycillin (AMOX) 1 g b.i.d. + MTR 250 mg q.i.d.; and (C) LNS 30 mg b.i.d. + CLR 250 mg b.i.d. + AMOX 1 g b.i.d. Results: Two months after therapy, the eradication rates of the three treatments, expressed using both intention‐to‐treat and per‐protocol analyses were, respectively; group A, 86 and 91.5%; group B, 80 and 87%; group C, 82 and 89.1%. After therapy, a significant reduction in epigastric pain (P < 0.001), heartburn (P = 0.02), dyspepsia (P < 0.001) and vomiting (P < 0.005) was observed independently of the success of H. pylori eradication. A significantly higher percentage of asymptomatic patients were in the GU‐DU group than in CG group (87.7 vs 70.0%, P = 0.032). After therapy, 33 subjects still suffered from symptoms. Persistence of symptoms was significantly associated with an endoscopic diagnosis of oesophagitis and not with H. pylori infection. Patients cured of H. pylori infection showed a significant decrease in the histological activity of both antral and body gastritis (P < 0.0001), a significant drop in immunoglobulin (Ig) G anti‐H. pylori antibodies (P < 0.0001) and pepsinogen (PG) C (P< 0.0001) and an increase in the PGA/PGC ratio (P < 0.0001). Conclusions: The 7 day, lansoprazole‐based triple therapy was well tolerated and highly effective in the cure of H. pylori infection, the reduction of symptoms, chronic gastritis activity and serum levels of IgG anti‐H. pylori antibodies and PGC. Persistence of symptoms after therapy was significantly higher in CG than GU and DU patients and was significantly associated with oesophagitis.
- 1 March 1999
- Vol. 31 (2) , 137-53
Aging and the gastrointestinal tract.
The aim of the present review is to summarize the most recent progress in gastroenterological topics, particularly of the upper gastrointestinal tract, which are of special interest in the elderly. The changes in oesophageal function, particularly disorders of motility, may explain, only in part, the unique clinical characteristics of oesophageal pathologies in the elderly. Dysphagia and gastro-oesophageal reflux disease present diagnostic, clinical and therapeutic characteristics that need to be studied with attention to avoid eventual disability, an impairment of nutritional status and a reduction in the quality of life. Aging, per se, does not significantly modify gastric aggressive factors, however, a selective and specific reduction in some gastric defensive mechanisms seems to occur with aging. The prevention of gastric mucosal injury, particularly that due to drugs, requires a better understanding of these age-related changes. Helicobacter pylori infection in the elderly presents peculiar epidemiological aspects particularly for subjects living in nursing homes. An understanding of Helicobacter pylori-related histological modifications of the gastric mucosa, particularly intestinal metaplasia, gastric atrophy and gastric cancer, the incidence of which seems to be both age- and Helicobacter pylori-related, is greatly needed. Moreover, some diagnostic and therapeutic aspects of Helicobacter pylori infection, i.e., the role of serology and the efficacy, side effects and compliance of drug therapies, are specific for the elderly and require a unique clinical approach. Bleeding is dramatically more frequent in this population. The identification of risk factors, i.e., drugs, pathophysiological mechanisms, i.e., the possible relationship between non-steroidal anti-inflammatory drugs and Helicobacter pylori infection, along with the clinical presentation in the elderly patient, must be the foundation of preventive medical care in geriatric gastroenterology.
- 1 March 1999
- Vol. 31 (2) , 137-53
Aging and the gastrointestinal tract.
The aim of the present review is to summarize the most recent progress in gastroenterological topics, particularly of the upper gastrointestinal tract, which are of special interest in the elderly. The changes in oesophageal function, particularly disorders of motility, may explain, only in part, the unique clinical characteristics of oesophageal pathologies in the elderly. Dysphagia and gastro-oesophageal reflux disease present diagnostic, clinical and therapeutic characteristics that need to be studied with attention to avoid eventual disability, an impairment of nutritional status and a reduction in the quality of life. Aging, per se, does not significantly modify gastric aggressive factors, however, a selective and specific reduction in some gastric defensive mechanisms seems to occur with aging. The prevention of gastric mucosal injury, particularly that due to drugs, requires a better understanding of these age-related changes. Helicobacter pylori infection in the elderly presents peculiar epidemiological aspects particularly for subjects living in nursing homes. An understanding of Helicobacter pylori-related histological modifications of the gastric mucosa, particularly intestinal metaplasia, gastric atrophy and gastric cancer, the incidence of which seems to be both age- and Helicobacter pylori-related, is greatly needed. Moreover, some diagnostic and therapeutic aspects of Helicobacter pylori infection, i.e., the role of serology and the efficacy, side effects and compliance of drug therapies, are specific for the elderly and require a unique clinical approach. Bleeding is dramatically more frequent in this population. The identification of risk factors, i.e., drugs, pathophysiological mechanisms, i.e., the possible relationship between non-steroidal anti-inflammatory drugs and Helicobacter pylori infection, along with the clinical presentation in the elderly patient, must be the foundation of preventive medical care in geriatric gastroenterology.